Credit: mannKind. Furoscix ReadyFlow offers a rapid, outpatient alternative for acute fluid overload management in heart failure and chronic kidney disease. Furoscix ReadyFlow demonstrated a ...
Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.
Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...
In the RAS G12-mutated population, daraxonrasib significantly improved median OS (13.2 vs 6.6 months) and median PFS (7.3 vs 3.5 months) compared with chemotherapy. The Food and Drug Administration ...
In a scientific statement, the association states that consuming caffeinated coffee linked to reduced risks for type 2 diabetes, heart disease, stroke, heart failure.
Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.
Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.
The analysis included 75 brick-and-mortar weight-loss clinics and medical spas offering compounded GLP-1 RAs. HealthDay News — Despite the end of nationwide shortages of glucagon-like peptide-1 ...
Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.
In the CALIBRATE trial, 76% of encaleret-treated patients normalized both blood and urine calcium at week 24 vs 4% on standard of care, while 91% achieved intact PTH restoration.
TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results